Please ensure Javascript is enabled for purposes of website accessibility

Why Greenwich LifeSciences Stock Skyrocketed Today

By Keith Speights - Mar 8, 2021 at 3:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered an important new hire.

What happened

Shares of Greenwich LifeSciences (GLSI 6.92%) were skyrocketing 48.8% higher as of 3:19 p.m. EST on Monday. The huge jump came after the company announced the hiring of Jaye Thompson as vice president of clinical and regulatory affairs.

So what

It's unusual for the addition of a new vice president to provide such a massive catalyst for a biotech stock. In this case, though, the hiring of Thompson increased investors' confidence about the potential for success in the late-stage study of Greenwich's GP2 cancer immunotherapy candidate in treating breast cancer.

Scientist looking through a microscope

Image source: Getty Images.

Thompson has advised Greenwich in the past. Now, however, she will work with the company full-time with her primary focus being to guide the pivotal study of GP2. Thompson brings an impressive track record of more than 30 years of experience in pharmaceutical and medical device product development.

Greenwich LifeSciences CEO Snehal Patel stated that bringing Thompson on board will enable the company to begin enrolling participants in its late-stage study of GP2 at multiple sites. He also said that her experience will help Greenwich "optimize the utilization of our cash resources" as the company moves forward with the pivotal study.

Now what

The next major milestone for Greenwich is to kick off the planned phase 3 study of GP2. The lead site will be the Baylor College of Medicine. Look for the company to announce other sites as well in the coming months. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Greenwich LifeSciences, Inc. Stock Quote
Greenwich LifeSciences, Inc.
$8.50 (6.92%) $0.55

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.